A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology

Authors: Al-Batran, S.-E., Mueller, D.W., Rafiyan, M.-R., Kiselicki, D., Atmaca, A., Habibzada, T., Mueller, C., Brignone, C., Triebel, F., Loose, M., Schaaf, M., Sookthai, D., Eickhoff, R., Jaeger, E., Goetze, T.O.

Source: In ESMO Open October 2023 8(5)

Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort

Authors: Tikk, K., Sookthai, D., Johnson, T., Rinaldi, S., Romieu, I., Tjønneland, A., Olsen, A., Overvad, K., Clavel-Chapelon, F., Baglietto, L., Boeing, H., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Palli, D., Pala, V., Tumino, R., Rosso, S., Panico, S., Agudo, A., Menéndez, V., Sánchez, M.-J., Amiano, P., Huerta Castaño, J.M., Ardanaz, E., Bueno-de-Mesquita, H.B., Monninkhof, E., Onland-Moret, C., Andersson, A., Sund, M., Weiderpass, E., Khaw, K.-T., Key, T.J., Travis, R.C., Gunter, M.J., Riboli, E., Dossus, L., Kaaks, R. ^*

Source: In Annals of Oncology July 2014 25(7):1422-1428

The effects of intermittent calorie restriction on metabolic health: Rationale and study design of the HELENA Trial

Authors: Schübel, R., Graf, M. E., Nattenmüller, J., Nabers, D., Sookthai, D., Gruner, L. F., Johnson, T., Schlett, C. L., von Stackelberg, O., Kirsten, R.

Source: CONTEMPORARY CLINICAL TRIALS. 51:28-33

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN381679699&indx=1&recIds=ETOCRN381679699

Mid- and long-term correlations of plasma metabolite concentrations measured by a targeted metabolomics approach

Authors: Kühn, T., Sookthai, D., Rolle-Kampczyk, U., Otto, W., Bergen, M., Kaaks, R., Johnson, T.

Source: METABOLOMICS. 12(12):1-7

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN380898583&indx=1&recIds=ETOCRN380898583

Risk factors for cancers of unknown primary site: Results from the prospective EPIC cohort

Authors: Kaaks, R., Sookthai, D., Hemminki, K., Krmer, A., Boeing, H., Wirflt, E., Weiderpass, E., Overvad, K., Tjnneland, A., Olsen, A.

Source: INTERNATIONAL JOURNAL OF CANCER. 135(10):2475-2481

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN359575099&indx=1&recIds=ETOCRN359575099

Primary Preventive Potential for Stroke by Avoidance of Major Lifestyle Risk Factors: The European Prospective Investigation Into Cancer and Nutrition-Heidelberg Cohort

Authors: Tikk, K., Sookthai, D., Monni, S., Gross, M.-L., Lichy, C., Kloss, M., Kaaks, R.

Source: STROKE -DALLAS-. 45(7):2041-2046

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN356762986&indx=1&recIds=ETOCRN356762986

Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status-Results from the EPIC cohort

Authors: Kaaks, R., Tikk, K., Sookthai, D., Schock, H., Johnson, T., Tjnneland, A., Olsen, A., Overvad, K., Clavel-Chapelon, F., Dossus, L.

Source: INTERNATIONAL JOURNAL OF CANCER. 134(8):1947-1957

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN347275527&indx=1&recIds=ETOCRN347275527

Home parenteral nutrition (HPN) using individually compounded PN via A 7/8/9-Multi-chamber system versus PN via 2/3-chamber bags in subjects with metastatic or localized solid tumors requiring HPN - The IKF-010 Pekannuss trial

Authors: Al-Batran, S.-E., Roetzer, I., Wohn, L., Blau, W., Zander, T., Luley, K.B., Ivanyi, P., Hofheinz, R.-D., Groschek, M., Kreiss-Sender, J., Baur, C., Wolff, T., Wenning, B., Decker-Baumann, C., Bouymayan, S., Sookthai, D., Schaaf, M., Riedel, J., Goetze, T.O., Haag, G.M.

Source: In Clinical Nutrition ESPEN December 2023 58:440-441

P-30 Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy – final results of the phase II RE-ExPEL study

Authors: Goetze, T., Stein, A., Lorenzen, S., Habibzada, T., Goekkurt, E., Herhaus, P., Sookthai, D., Brulin, T., Ihrig, K., Pauligk, C., Al-Batran, S.

Source: In Annals of Oncology June 2023 34 Supplement 1:S23-S24

49P Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy: Final results of the phase II RE-ExPEL study

Authors: Goetze, T.O., Stein, A., Lorenzen, S., Habibzade, T., Goekkurt, E., Herhaus, P., Sookthai, D., Ihrig, K., Pauligk, C., Al-Batran, S-E.

Source: In Annals of Oncology November 2022 33 Supplement 9:S1448-S1448

LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group

Authors: Perkhofer, L., Striefler, J.K., Sinn, M., Opitz, B., Goetze, T.O., Gallmeier, E., Fischer von Weikersthal, L., Jacobasch, L., Waldschmidt, D., Niedermeier, M., Sohm, M., Sookthai, D., Berger, A., Beutel, A., Seufferlein, T., Ettrich, T.J.

Source: In Annals of Oncology September 2021 32 Supplement 5:S1282-S1282

1424MO Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma– Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM

Authors: Al-Batran, S-E., Hofheinz, R.D., Schmalenberg, H., Strumberg, D., Goekkurt, E., Angermeier, S., Zander, T., Potenberg, J., Kopp, H-G., Pink, D., Siegler, G.M., Schenk, M., De Vita, F., Maiello, E., Gaiser, T., Sookthai, D., Bankstahl, U.S., Pauligk, C., Götze, T.O., Homann, N.

Source: In Annals of Oncology September 2020 31 Supplement 4:S901-S901

1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma

Authors: Al-Batran, S-E., Haag, G.M., Ettrich, T.J., Borchert, K., Kretzschmar, A., Teschendorf, C., Siegler, G.M., Ebert, M., Goekkurt, E., Welslau, M.K., Mahlberg, R.J.C., Homann, N., Pink, D., Bechstein, W.O., Reichardt, P., Gaiser, T., Sookthai, D., Pauligk, C., Goetze, T.O., Hofheinz, R.D.

Source: In Annals of Oncology September 2020 31 Supplement 4:S899-S899

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.